Bellevue Life Sciences Acquisition (BLAC) Stock Price, News & Analysis

Company Overview

Bellevue Life Sciences Acquisition Corp. (NASDAQ: BLAC) is a special purpose acquisition company organized as a Delaware corporation. The company completed its initial public offering in 2021, raising gross proceeds to pursue a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more life sciences businesses.

BLAC’s principal activity is to identify and complete a business combination with a target operating company in the life sciences sector. The company focuses on businesses involved in biotechnology, biopharmaceutical development, medical devices and diagnostics, seeking opportunities where it can provide strategic capital and industry expertise to support growth and innovation.

The sponsor, Bellevue Life Sciences, is a venture-focused investor with a track record in healthcare and life sciences investing. Bellevue Life Sciences brings to BLAC an experienced team of investment professionals and advisors with backgrounds in drug discovery, clinical development, regulatory affairs and corporate finance. This expertise is intended to support target companies through commercialization and growth phases.

Bellevue Life Sciences Acquisition Corp. evaluates potential targets across North America and Europe, aiming to leverage its sponsor’s global network of life sciences partnerships. The company’s management team and board of directors draw on decades of combined experience in healthcare research, development and capital markets, positioning BLAC to execute a value-creating transaction in the dynamic life sciences industry.

Key Stats

• Today's Range: $0.55 to $0.58
• 50-Day Range: $0.50 to $1.51
• 52-Week Range: $3.01 to $13.40
• Volume: 263,696 shs
• Average Volume: 22,626 shs
• Market Capitalization: $2.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BLAC Stock Analysis - Frequently Asked Questions

How have BLAC shares performed this year?

Bellevue Life Sciences Acquisition's stock was trading at $11.53 at the start of the year. Since then, BLAC stock has decreased by 95.2% and is now trading at $0.5545.

How do I buy shares of Bellevue Life Sciences Acquisition?

Shares of BLAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bellevue Life Sciences Acquisition own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellevue Life Sciences Acquisition investors own include Andretti Acquisition Corp. II (POLEU), Agriculture & Natural Solutions Acquisition (ANSC), Alpha Star Acquisition (ALSA), Alchemy Investments Acquisition Corp 1 (ALCY), AI Transportation Acquisition (AITR), Aimfinity Investment Corp. I (AIMAU) and Aimei Health Technology (AFJK).

Company Calendar

• Today: 9/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Holding & other investment offices
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BLAC
• Previous Symbol: NASDAQ:BLAC
• CIK: 1840425
• Web: www.bellevuespac.com
• Phone: 425-635-7700
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,041,000
• Free Float: 2,680,000
• Market Cap: $2.24 million
• Optionable: Not Optionable
• Beta: -0.08